Skip to main content

Table 2 General characteristics values of lipoprotein lipase PvuII genotypes in the non-metabolic syndrome and metabolic syndrome groups

From: The association of lipoprotein lipase PvuII polymorphism and niacin intake in the prevalence of metabolic syndrome: a KMSRI-Seoul study

 

Total subjects (n = 548)

Non-MetSyn

MetSyn

P value

P1P1 (n = 35)

P1P2 (n = 107)

P2P2 (n = 128)

P1P1 (n = 26)

P1P2 (n = 134)

P2P2 (n = 118)

Among 6 groups

Non-MetSyn versus MetSyn

Metabolic syndrome risk factors

Waist (cm)

88.57 ± 9.23

82.23 ± 10.33a

85.10 ± 8.25b

83.80 ± 8.85ab,*

93.15 ± 7.09c

92.74 ± 7.73c

92.99 ± 6.95c

<0.001

<0.001

SBP (mmHg)

129.28 ± 15.03

122.00 ± 9.35a

123.09 ± 13.94a

121.79 ± 12.49a

138.08 ± 13.78b

136.69 ± 14.49b

134.81 ± 13.38b

<0.001

<0.001

DBP (mmHg)

81.83 ± 11.28

76.89 ± 9.34a

77.75 ± 10.38a

76.75 ± 9.54a

89.69 ± 10.47c

86.54 ± 10.75b

85.45 ± 10.64b,*

<0.001

<0.001

Fasting glucose (mmol/L)

5.92 ± 1.45

5.19 ± 0.62a

5.35 ± 0.76a

5.50 ± 1.52a

5.99 ± 0.80b

6.39 ± 1.52c

6.54 ± 1.61c

<0.001

<0.001

Triglycerides (mmol/L)

1.87 ± 1.14

1.08 ± 0.52a

1.30 ± 0.70a

1.30 ± 0.73a,*

2.65 ± 1.18c

2.29 ± 1.14b

2.57 ± 1.24c,*

<0.001

<0.001

HDL cholesterol (mmol/L)

1.26 ± 0.33

1.51 ± 0.38d

1.40 ± 0.33c

1.37 ± 0.34c,*

1.20 ± 0.32b

1.13 ± 0.23ab

1.09 ± 0.24a,**

<0.001

<0.001

Anthropometric, lipid-related variables

BMI (kg/m2)

25.43 ± 3.21

23.19 ± 2.95a

24.33 ± 2.99b

24.25 ± 3.07b,*

26.56 ± 2.96c

26.70 ± 2.85c

26.68 ± 2.87c

<0.001

<0.001

Total cholesterol (mmol/L)

4.99 ± 0.93

4.97 ± 1.03a

5.03 ± 0.97ab

4.93 ± 0.91a

5.26 ± 0.77b

5.02 ± 1.00ab

4.91 ± 0.82a,*

0.139

0.693

LDL cholesterol (mmol/L)

2.90 ± 0.86

3.08 ± 0.71c

3.04 ± 0.88bc

2.99 ± 0.77bc

2.93 ± 0.73bc

2.83 ± 0.91ab

2.70 ± 0.88a

<0.001

<0.001

Insulin resistance-related variables and lipoprotein lipase mass

Insulin (ulU/mL)

5.17 ± 4.09

(n = 536)

3.58 ± 2.58a

(n = 34)

4.53 ± 3.26a

(n = 106)

4.32 ± 3.67a

(n = 122)

5.80 ± 3.23b

(n = 26)

6.03 ± 4.56b

(n = 131)

5.99 ± 4.74b

(n = 117)

<0.001

<0.001

HOMA-IR

1.40 ± 1.37

0.83 ± 0.58a

1.09 ± 0.82a

1.05 ± 0.90a

1.53 ± 0.85b

1.76 ± 1.85b

1.79 ± 1.58b

<0.001

<0.001

Lipoprotein lipase mass (ng/mL)

39.64 ± 18.05

(n = 369)

56.50 ± 18.42d

(n = 25)

45.21 ± 17.54c

(n = 70)

38.24 ± 15.92b,***

(n = 85)

38.31 ± 13.22b

(n = 16)

38.70 ± 17.25b

(n = 95)

32.18 ± 17.68a,**

(n = 78)

<0.001

<0.001

Nutrient intake (n = 269)

Energy (kcal)

1,829.30 ± 684.38 (n = 269)

1,750.80 ± 600.99 (n = 18)

1,824.12 ± 816.75 (n = 51)

1,720.54 ± 703.90 (n = 59)

1,814.82 ± 630.87 (n = 11)

1,883.20 ± 655.05 (n = 71)

1,904.33 ± 598.94 (n = 59)

0.330

0.043

Energy-adjusted niacin (mg)

16.89 ± 4.98

14.94 ± 3.95a

17.33 ± 5.43b

16.67 ± 3.72ab,*

18.12 ± 3.76b

17.21 ± 5.17b

16.70 ± 5.78ab

0.125

0.370

Frequency of life style (n = 500)

Physical activity

 Yes

326 (66.0%)

20 (6.1%)

62 (19.0)

76 (23.3%)

15 (4.6%)

82 (25.2%)

71 (21.8%)

0.928

0.486

 No

168 (34.0%)

10 (6.0%)

36 (21.4%)

36 (21.4%)

9 (5.4%)

42 (25.0%)

35 (20.8%)

Smoking habits

 Non-smoker

241 (48.2%)

21 (8.7%)

52 (21.6%)

72 (29.9%)*

9 (3.7%)

58 (24.1%)

29 (12.0%)***

<0.001

<0.001

 Ex-smoker

139 (27.8%)

4 (2.9%)

24 (17.3%)

25 (18.0%)

5 (3.6%)

35 (25.2%)

46 (33.1%)

 Smoker

120 (24.0%)

7 (5.8%)

22 (18.3%)

16 (13.3%)

11 (9.2%)

33 (27.5%)

31 (25.8%)

Alcohol consumption

 Non-drinker

164 (32.8%)

16 (9.8%)

34 (20.7%)

41 (25.0%)

5 (3.0%)

42 (25.6%)

26 (15.9%)*

<0.001

0.001

 Ex-drinker

31 (6.2%)

1 (3.2%)

6 (19.4%)

3 (9.7%)

0 (0.0%)

11 (35.5%)

10 (32.3%)

 Drinker

305 (61.0%)

15 (4.9%)

58 (19.0%)

69 (22.6%)

20 (6.6%)

73 (23.9%)

70 (23.0%)

  1. Statistical differences among groups were determined by ANOVA and Chi-square test for continuous and categorical variables, respectively. Data are expressed as the mean ± SD and number (%)
  2. Values with different letters were significantly different among the groups
  3. SBP systolic blood pressure, DBP diastolic blood pressure, BMI body mass index, HOMA-IR homeostasis model assessment of insulin resistance
  4. Significant differences between LPL PvuII genotype in each non-MetSyn and MetSyn were described by * P < 0.05; ** P < 0.01; *** P < 0.001